Literature DB >> 28579723

Pimavanserin (Nuplazid): A Treatment for Hallucinations and Delusions Associated With Parkinson's Disease.

Martin Paspe Cruz.   

Abstract

Pimavanserin (Nuplazid) for the treatment of hallucinations and delusions associated with Parkinson's disease.

Entities:  

Year:  2017        PMID： 28579723      PMCID： PMC5440097     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  18 in total

1.  Prevalence of psychotic symptoms in a community-based Parkinson disease sample.

Authors:  Joel Mack; Peter Rabins; Karen Anderson; Susanne Goldstein; Stephen Grill; Elaina S Hirsch; Susan Lehmann; John T Little; Russell L Margolis; Justin Palanci; Gregory Pontone; Howard Weiss; James R Williams; Laura Marsh
Journal:  Am J Geriatr Psychiatry       Date:  2012-02       Impact factor: 4.105

2.  Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.

Authors:  G Fénelon; F Mahieux; R Huon; M Ziégler
Journal:  Brain       Date:  2000-04       Impact factor: 13.501

3.  Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study.

Authors:  D Aarsland; J P Larsen; J L Cummins; K Laake
Journal:  Arch Neurol       Date:  1999-05

4.  Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group.

Authors:  Bernard Ravina; Karen Marder; Hubert H Fernandez; Joseph H Friedman; William McDonald; Diane Murphy; Dag Aarsland; Debra Babcock; Jefferey Cummings; Jean Endicott; Stewart Factor; Wendy Galpern; Andrew Lees; Laura Marsh; Mark Stacy; Katrina Gwinn-Hardy; Valerie Voon; Christopher Goetz
Journal:  Mov Disord       Date:  2007-06-15       Impact factor: 10.338

5.  Longitudinal outcome of Parkinson's disease patients with psychosis.

Authors:  S A Factor; P J Feustel; J H Friedman; C L Comella; C G Goetz; R Kurlan; M Parsa; R Pfeiffer
Journal:  Neurology       Date:  2003-06-10       Impact factor: 9.910

6.  A 12-year population-based study of psychosis in Parkinson disease.

Authors:  Elin B Forsaa; Jan Petter Larsen; Tore Wentzel-Larsen; Christopher G Goetz; Glenn T Stebbins; Dag Aarsland; Guido Alves
Journal:  Arch Neurol       Date:  2010-08

7.  Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.

Authors:  Lon S Schneider; Karen S Dagerman; Philip Insel
Journal:  JAMA       Date:  2005-10-19       Impact factor: 56.272

8.  Early dopaminergic drug-induced hallucinations in parkinsonian patients.

Authors:  C G Goetz; C Vogel; C M Tanner; G T Stebbins
Journal:  Neurology       Date:  1998-09       Impact factor: 9.910

9.  Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson disease.

Authors:  Howard D Weiss; Laura Marsh
Journal:  Neurol Clin Pract       Date:  2012-12

Review 10.  Epidemiology of psychosis in Parkinson's disease.

Authors:  Gilles Fénelon; Guido Alves
Journal:  J Neurol Sci       Date:  2009-09-08       Impact factor: 3.181
View more
  9 in total

Review 1.  Serotonergic system, cognition, and BPSD in Alzheimer's disease.

Authors:  Saikat Chakraborty; Jack C Lennon; Sridhar A Malkaram; Yan Zeng; Daniel W Fisher; Hongxin Dong
Journal:  Neurosci Lett       Date:  2019-04-01       Impact factor: 3.046

Review 2.  Current Agents in Development for Treating Behavioral and Psychological Symptoms Associated with Dementia.

Authors:  Mehnaz Ahmed; Marlene Malik; Johannes Teselink; Krista L Lanctôt; Nathan Herrmann
Journal:  Drugs Aging       Date:  2019-07       Impact factor: 3.923

Review 3.  Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression.

Authors:  Susan Ling; Felicia Ceban; Leanna M W Lui; Yena Lee; Kayla M Teopiz; Nelson B Rodrigues; Orly Lipsitz; Hartej Gill; Mehala Subramaniapillai; Rodrigo B Mansur; Kangguang Lin; Roger Ho; Joshua D Rosenblat; David Castle; Roger S McIntyre
Journal:  CNS Drugs       Date:  2021-11-17       Impact factor: 5.749

4.  Pharmacological Management of Neuropsychiatric Symptoms of Dementia.

Authors:  Lauren B Gerlach; Helen C Kales
Journal:  Curr Treat Options Psychiatry       Date:  2020-09-02

5.  Atypical antipsychotics for Parkinson's disease psychosis: a systematic review and meta-analysis.

Authors:  Han Zhang; Limin Wang; Yafei Fan; Lianhong Yang; Xiaojun Wen; Yunyun Liu; Zhonglin Liu
Journal:  Neuropsychiatr Dis Treat       Date:  2019-07-29       Impact factor: 2.570

6.  A Systematic Review and Case Series of Ziprasidone for Psychosis in Parkinson's Disease.

Authors:  John R Younce; Albert A Davis; Kevin J Black
Journal:  J Parkinsons Dis       Date:  2019       Impact factor: 5.568

Review 7.  The Pharmacology of Visual Hallucinations in Synucleinopathies.

Authors:  Mirella Russo; Claudia Carrarini; Fedele Dono; Marianna Gabriella Rispoli; Martina Di Pietro; Vincenzo Di Stefano; Laura Ferri; Laura Bonanni; Stefano Luca Sensi; Marco Onofrj
Journal:  Front Pharmacol       Date:  2019-12-09       Impact factor: 5.810

8.  Identification of Potential Parkinson's Disease Drugs Based on Multi-Source Data Fusion and Convolutional Neural Network.

Authors:  Jie Liu; Dongdong Peng; Jinlong Li; Zong Dai; Xiaoyong Zou; Zhanchao Li
Journal:  Molecules       Date:  2022-07-26       Impact factor: 4.927

9.  Screening, Diagnosis, and Management of Parkinson's Disease Psychosis: Recommendations From an Expert Panel.

Authors:  Rajesh Pahwa; Stuart H Isaacson; Gary W Small; Yasar Torres-Yaghi; Fernando Pagan; Marwan Sabbagh
Journal:  Neurol Ther       Date:  2022-07-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.